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A B S T R A C T
A prospective cohort study was performed to
collect baseline data concerning surgical site
infections (SSIs) and antimicrobial prophylaxis
(AMP) in a remote sub-Saharan district hospital.
The SSI rate of 22% was high. Most (88%) of the
patients received prophylaxis after incision, and
only 5% within the 30-min period before incision.
Of all pathogens isolated from SSIs, 60% were
resistant to the agent administered. The antibiot-
ics given most frequently were chloramphenicol
(60%), aminopenicillins (23%) and benzylpenicil-
lin (15%). Staphylococcus aureus (36%), Escherichia
coli (5%) and enterococci (4%) were the patho-
gens isolated most commonly from SSIs.
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Surgical site infections (SSIs) are the second most
common cause of nosocomial infection, resulting
in considerable morbidity and mortality. Antimi-
crobial prophylaxis (AMP) reduces the rate of
SSI in non-clean surgery. In accordance with
guidelines, perioperative AMP is administered
routinely in industrialised countries to all patients
who qualify [1,2]. Data concerning comparative
perioperative AMP in non-industrialised and
industrialised nations are scarce [3–6]. The present
study provides, for the first time, data concerning
AMP in a rural sub-Saharan district hospital.
The study was conducted in the 82-bed depart-
ment of general surgery, which includes gynae-
cology and obstetrics, of the St Francis Designated
District Hospital in Ifakara, southern Tanzania.
The St Francis Designated District Hospital is a
371-bed hospital that serves a region with a
population of >550 000. A mean of 155 surgical
procedures are performed every month in the two
main operating rooms. Between November 2003
and March 2004, all consecutive adult patients
admitted for surgery were enrolled in the study.
Data concerning patient characteristics, laborat-
ory results, type of surgical intervention and
administration of AMP were recorded continu-
ously by study nurses (24 h, 7 days a week). No
written guidelines concerning the use of AMP
were available in the hospital; antibiotics and
dosages were chosen by the surgeon.
In cases of suspected SSI, the site of infection
was documented with a digital camera and swab
samples were taken. During the study, data were
reviewed and checked prospectively by a senior
infectious diseases specialist. Material from swabs
was analysed by Gram’s stain and plated on
CHROMagar Orientation and CHROMagar Sta-
phylococcus aureus (Becton Dickinson, Heidelberg,
Germany) in the local laboratory. Colonies isola-
ted were subcultured and transported to the
Microbiology Laboratory, University Hospital Ba-
sel, Switzerland, for further analysis using stand-
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ard microbiological methods [7,8]. SSIs were
classified according to CDC recommendations,
i.e., superficial, deep, organ or space [1]. Statistical
analyses were carried out using SAS v.8 software
(SAS Inc., Chicago, IL, USA).
In total, 613 patients underwent surgery during
the 4-month period of study, of whom 527 (84%
female; median age 28 years, range 16–84 years)
qualified for routine AMP. Of these, 114 (21.6%)
developed an SSI (Fig. 1); 49 (43%) infections
were superficial, 51 infections (45%) were deep,
and 14 (12%) infections were organ or space
SSIs. Seven (1%) patients died; five deaths were
possibly attributable and two deaths were clearly
attributable to SSI. Twenty-two (19%) SSIs were
identified only by post-discharge surveillance.
Caesarian sections (n = 332, 63%) were the surgi-
cal interventions performed most frequently, fol-
lowed by other gynaecological procedures (11%).
Overall, 56% of all interventions were classified
as emergencies. The median duration of the most
frequent interventions was 30 min (range 10–
150 min). In total, 222 (42.5%) patients failed to
return for a follow-up visit (on day 30), presum-
ably because of the need to travel >8 h to reach
the hospital; however, none showed evidence of
SSI at discharge.
AMP was administered to 524 (99%) patients;
prophylaxis was not given to three patients for
unknown reasons. The antibiotics used most
frequently were chloramphenicol (n = 314, 60%)
and aminopenicillins, such as ampicillin (n = 122,
23%) or benzylpenicillin (n = 77, 15%). In 118
(23%) of 524 cases, more than one agent was
administered prophylactically. Ampicillin and
cloxacillin (n = 69, 59%) was the combination
used most often.
Overall, 88% (460 ⁄ 527) of patients received
prophylaxis after incision, including 55% who
received prophylaxis >30 min after incision
(Fig. 2). Only 5% of cases received prophylaxis
within the 60-min period before surgery, but
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Fig. 1. Patient enrolment in the study. aProphylaxis indicated, i.e., according to CDC definition of clean or clean-
contaminated wounds (class I or class II). bTreatment situation, i.e., according to CDC definition of dirty or dirty-infected
wounds (class III or class IV). SSI, surgical site infection.
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Fig. 2. Time of administration of
antimicrobial prophylaxis in relation
to the incidence of surgical site
infections.
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>90% of patients received prophylaxis for a
duration of 5 days. AMP was not effective against
60% of the pathogens isolated. The pathogen
found most frequently was S. aureus in 36%
(n = 41) of the cases, followed by Escherichia coli
in 5% (n = 6) and enterococci in 4% (n = 4). Other
clinically relevant bacteria, e.g., Klebsiella spp.,
Proteus spp., other Enterobacteriaceae, Pseudomon-
as aeruginosa and Acinetobacter spp. were found in
7% of cases. Coagulase-negative staphylococci,
Corynebacterium spp. and Bacillus spp. (n = 34)
were considered to be contaminants and were
grouped together with ‘no growth’ (n = 21; total,
n = 55, 48%). Chloramphenicol resistance was
detected in 33% (n = 13) of S. aureus, 35% (n = 2)
of E. coli and 25% (n = 1) of enterococci. Resist-
ance to penicillin was detected in 95% of S. aureus
isolates, but methicillin-resistant S. aureus com-
prised only one of 114 isolates in this remote
hospital. Surprisingly, 29% (4 ⁄ 14) of all Gram-
negative pathogens expressed extended-spectrum
b-lactamases. Two isolates of enterococi were
insusceptible to vancomycin.
The SSI rate of 22% was high compared with
incidence rates reported from other continents
[9,10]. The principles of asepsis, disinfection and
sterilisation, as well as surgical techniques, were
not deviated from significantly. Sterilisation was
performed with a hot-air steriliser; however
shortage of disposable items was common.
Nevertheless, an assessment of the infrastructure
was unable to explain the high rate of SSI in this
relatively young population [11], and inappropri-
ate AMP may have contributed significantly to
the rate of SSI. First, AMP was not directed
against the spectrum and corresponding resist-
ance patterns of the pathogens causing SSIs. It is
of concern that healthcare providers working in
this remote hospital were already confronted with
highly resistant pathogens, including methicillin-
resistant S. aureus, extended-spectrum b-lacta-
mase-producing organisms and enterococci that
were insusceptible to vancomycin. Second, AMP
was generally not administered during the recom-
mended time window, thereby severely reducing
the effect of prophylaxis [12]. US guidelines
recommend that the optimal time window for
administration of AMP is <60 min before incision
[13,14]. The goal of AMP is to achieve serum and
tissue drug levels that exceed the MICs for the
organisms likely to be encountered during sur-
gery. Although multiple studies have demonstra-
ted no benefit for delayed AMP, this practice was
used in the current setting and is still common in
many institutions [15]. Moreover, AMP extended
for 5 days may favour the emergence of multiply
resistant pathogens [16]. Even the administration
of correctly timed antimicrobial agents did not
lower the infection rate in this study effectively,
probably because AMP was not active against the
pathogens encountered (Fig. 2).
Currently c. 700 million individuals live in sub-
Saharan Africa, with a high percentage having
access to only primary healthcare facilities. The
results of the present study underline the import-
ance of conducting further studies in this area,
and of establishing surveillance programmes to
allow the formulation of international guidelines
that take regions with limited resources into
account.
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A B S T R A C T
A retrospective cohort study evaluated the effect-
iveness and nephrotoxicity of intravenous colistin
monotherapy vs. colistin–meropenem combina-
tion therapy for patients with multidrug-resistant
Gram-negative bacterial infections. Fourteen pa-
tients received intravenous colistin monotherapy
and 57 received colistin–meropenem. No signifi-
cant differences were found concerning clinical
response of the infection (12 ⁄ 14 (85.7%) vs. 39 ⁄ 57
(68.4%), p 0.32) and development of nephrotox-
icity (0 ⁄ 14 (0%) vs. 4 ⁄ 57 (7%), p 0.58). A favour-
able association was revealed between survival
and treatment with colistin monotherapy com-
pared to colistin–meropenem (0 ⁄ 14 (0%) vs. 21 ⁄ 57
(36.8%) deaths, p 0.007), even after adjusting for
the variables for which significant differences
were found.
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Most recent clinical studies with polymyxins have
reported data concerning the clinical outcome for
patients treated with combinations of polymyxins
and various other antimicrobial agents [1–5].
However, data concerning the comparative effect-
iveness and toxicity of colistin monotherapy vs.
colistin–b-lactam combination therapy in patients
other than those with cystic fibrosis are lacking.
A retrospective cohort study was conducted
at the tertiary-care Henry Dunant hospital in
Athens, Greece. The study was approved by the
Institutional Review Board of the hospital.
Patients with infections caused by multidrug-
resistant Gram-negative bacilli who were hospi-
talised during the period October 2000 to May
2005 and were managed with intravenous
colistimethate sodium were identified from the
pharmacy electronic databases and included in
the study. Two physicians (PIR and SKK)
reviewed the patients’ records and classified
the outcomes. Patients were excluded from
further analysis if they had received intravenous
colistin therapy for <72 h. This group of patients
was compared with patients treated concomi-
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